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Summary
Background: We compared factors of inflammation – high
sensitivity C-reactive protein (hsCRP) and pentraxin-3
(PTX3), and we explored their relationship with coronary
artery disease (CAD). Also, we tested the usefulness of
hsCRP and PTX3 in the risk assessment of coronary steno-
sis development and the diagnostic ability of these bio-
markers to detect disease severity. 
Methods: The study group consisted of 93 CAD patients
undergoing coronary angiography. Patients were divided
into CAD(0), representing  subclinical stenosis, and CAD
( 1–3), representing significant stenosis in one, two or three
vessels. 
Results: We determined the concentration of lipid status
parameters, hsCRP and PTX3. We found significantly lower
PTX3 and hsCRP concentrations in CAD(0) than in
CAD(1–3) group. Concentration of PTX3 showed an in -
creasing trend with the increasing number of vessels affect-
ed. The area under ROC curve (AUC) for the combinations
of hsCRP and PTX3 with lipid parameters had useful accu-
racy for detecting CAD(1–3) patients (AUC=0.770,
p<0.001).
Kratak sadr`aj
Uvod: Visokoosetljivi C-reaktivni protein (hsCRP), kao
marker hroni~ne inflamacije, mo`e biti kori{}en u proceni
rizika od kardiovaskularnih bolesti. Cilj rada je bio da se
uporede markeri inflamacije hsCRP i pentraksin-3 (PTX3) i
da se ispita njihova veza sa koronarnom arterijskom
bole{}u (KAB). Tako|e, analiziran je zna~aj hsCRP i PTX3
u proceni rizika za koronarnu stenozu i dijagnosti~ka spo -
sobnost ovih biomarkera da utvrde te`inu bolesti.
Metode: Istra`ivanjem je obuhva}eno 93 pacijenta koji su
podvrgnuti koronarnoj angiografiji. Pacijenti sa sub kli -
ni~kom stenozom na koronarnim krvnim sudovima svrstani
su u KAB(0) grupu, dok su pacijenti sa  zna~ajnom steno-
zom na jednom, dva ili tri krvna suda svrstani u KAB(1–3)
grupu. Odre|ivane su koncentracije parametara lipidnog
statusa, hsCRP i PTX3.
Rezultati: Prose~ne koncentracije PTX3 i hsCRP kod paci-
jenata u KAB(0) grupi bile su zna~ajno ni`e u pore|enju sa
koncentracijama istih parametara u KAB(1–3) grupi. Kon -
cen tracija PTX3 pokazala je zna~ajnu pozitivnu korelaciju
sa porastom broja krvnih sudova zahva}enih stenozom.
Povr{ina ispod receiver operating characteristic krive (AUC)
J Med Biochem 2015; 34 (4) 441
Introduction
It is well known that immunological and inflam-
matory processes play a fundamental role in athero-
genesis (1), from the endothelial injury to acute clin-
ical manifestations (2). With the growing number of
coronary artery disease (CAD) population, the aim is
to find a biomarker, or the best combination of mark-
ers, which could help in identifying patients prone to
developing severe coronary stenosis, in early stages of
the atherosclerotic process. A variety of inflammatory
and other biochemical markers potentially related to
atherogenesis has been identified. These markers
include acute-phase reactants, pro-inflammatory
cytokines (interleukin-1, interleukin-6, tumor necrosis
factor-a), anti-inflammatory cytokines (interleukin-1
receptor antagonist, interleukin-10), matrix metallo-
proteinases (MMPs), cellular adhesion molecules, sol-
uble CD40 ligand (sCD40L), leukocyte myeloperoxi-
dase. Some of those markers have been shown to be
significantly associated with CAD (MMPs, sCD40L,
interleukin-1 receptor antagonist), but they are not
related to the severity of coronary stenosis. Science is
still searching for a marker that will have better diag-
nostic abilities than those previously examined, which
will be able to predict coronary stenosis and allow
avoiding unnecessary angiography in patients.
There are a few systemic inflammatory markers
that are recognized as established measures of car-
diovascular risk prediction (3, 4). C-reactive protein
(CRP), an acute phase reactant and a member of the
pentraxin superfamily, is one of the most actively stud-
ied biomarkers. CRP is widely accepted as a biomark-
er of systemic inflammation and routinely used as a
marker of infection and inflammation in clinical prac-
tice. Slightly elevated CRP concentrations may indi-
cate a low level of chronic inflammatory reaction in
patients at risk of developing cardiovascular disease
(CVD). High-sensitivity assays were developed with
improved sensitivity and precision at low concentra-
tions of CRP with the aim to detect subclinical inflam-
mation. The association between elevated high sensi-
tivity serum C-reactive protein (hsCRP) level and
increased risk of developing cardiovascular events has
been well established in many studies (5–7). How -
ever, CRP response is triggered by many disorders
unrelated to CVD.
Pentraxin-3 (PTX3) is the prototypic member of
a long pentraxin family and has C-terminal sequence
homology with short pentraxin CRP (8). However,
PTX3 and CRP are produced by different tissues and
may be involved in different pathophysiological mech-
anisms (9). Whereas hepatocytes are the main source
of CRP, PTX3 is produced at sites of inflammation by
a wide range of different cell types, including endo -
thelial cells, fibroblasts, monocytes, macro phages,
dendritic cells, adipocytes (9). PTX3 is produced
locally in atherosclerotic lesions (10) and was report-
ed to accumulate during atherosclerotic progression
in a murine model (11). 
Studies showed that deficiency of PTX3 is asso-
ciated with increased heart damage with a greater no-
reflow area and increased inflammatory response (12,
13). More recently, deficiency of PTX3 in apo lipo -
protein E knockout mice was shown to be associated
with increased atherosclerosis, macro phage accu mu -
lation within the plaque, and a more prono unced in -
flammatory profile in the vascular wall (11). Although
these observations indicate a cardiovascular protective
effect of PTX3, they also suggest the possibility that
the increased levels of PTX3 in subjects with CVD may
reflect a protective physiological response that corre-
lates with the severity of the disease. 
In this cross-sectional study we compared two
familiar factors of inflammation – hsCRP and PTX3,
and we examined their association with the extent of
coronary stenosis in patients with coronary artery dis-
ease (CAD). Also, we tested the usefulness of hsCRP
and PTX3 in the risk assessment of significant coro-
nary stenosis development using a multi-marker
approach, as well as the diagnostic ability of these two
biomarkers for detection of disease severity.
Material and Methods
Subjects
The study group consisted of 93 CAD patients
who were undergoing coronary angiography. All
patients were treated at the Institute for Cardio -
Conclusion: PTX3 is a promising independent diagnostic
marker for identifying patients with CAD, and a useful indi-
cator of disease progression. In all the analyses PTX3
showed better performance than hsCRP. A combination of
PTX3, hsCRP with the lipid status parameters provides risk
stratification of the development of coronary stenosis and
better classification than their individual application.
Keywords: high sensitivity C-reactive protein, pentraxin-
3, coronary artery disease, diagnostic accuracy
za kombinaciju hsCRP i PTX3 sa lipidnim parametrima po -
ka zala je zadovoljavaju}u ta~nost za detektovanje KAB(1–3)
pacijenata (AUC 0,770, p<0,001).
Zaklju~ak. Odre|ivanje PTX3 poma`e u identifikaciji osoba
sa KAB i mo`e biti korisno u proceni progresije bolesti. U
svim analizama PTX3 je, kao biomarker, pokazao bolje
dijagnosti~ke karakteristike u pore|enju sa hsCRP. Kombi -
nacija PTX3, hsCRP i parametara lipidnog statusa, u pore -
|enju sa njihovom pojedina~nom upotrebom, obezbe|uje
bolju klasifikaciju pacijenata u zavisnosti od te`ine KAB.
Klju~ne re~i: visokoosetljivi C-reaktivni protein, pen-
traksin-3, koronarna arterijska bolest, dijagnosti~ka ta~nost
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vascular Diseases located in the Clinical Centre of
Serbia in Belgrade. Two cardiologists unaware that
the patients were enrolled in the study reviewed all
the angio grams. 
All the enrolled patients completed a question-
naire that incorporated numerous risk-related issues.
The following factors were recorded: (1) smoking at
the time of angiography or at the time when the first
symptoms appeared; (2) hypertension (HT) indicated
by a systolic blood pressure ≥ 140 mm Hg, a diastolic
blood pressure ≥ 90 mm Hg or prescribed anti-hyper-
tensive medication; (3) body mass index (BMI), (4)
waist-to-hip ratio (W/H). We excluded patients with a
history of recent clinical infection, concurrent major
renal, hepatic or malignant disease, surgery or major
trauma during the month prior to study entry. Since
low-grade inflammation is usually defined when the
hsCRP concentration is below 10 mg/L we excluded
patients with concentrations of hsCRP ≥ 10 mg/L
which indicated a clinically relevant inflammatory
condition (14). The patients using statins in the treat-
ment were eliminated from analysis because of their
effect on inflammatory parameters. All patients gave
informed consent prior to their enrolment in the
study. The study was planned according to the ethical
guidelines following the Declaration of Helsinki. The
institutional review committee approved our study
protocol thereby following local biomedical research
regulations.
Patients were divided into two groups: CAD(0)
representing stenosis less than 50% or subclinical
stenosis (43 patients) and CAD(1–3) representing
stenosis above 50% in one or more vessels – signifi-
cant stenosis (50 patients). A further division of the
patients was performed according to the extent of
CAD. We subdivided CAD(1–3) group into 3 groups:
CAD(1) included 14 patients (28%) with significant
stenosis of one vessel, CAD(2) included 20 patients
(40%) with significant stenosis of two vessels and
CAD(3) included 16 patients (32%) with significant
stenosis of three vessels.
Methods
Blood samples were obtained from the patients
after overnight fasting. Peripheral venous blood was
drawn into collection tubes containing ethylene
diamine-tetraacetic acid (EDTA) or serum separator
gel. Lipid and lipoprotein parameters were deter-
mined in EDTA plasma, hsCRP and PTX3 in serum.
Aliquots of plasma and serum were stored at –80 °C
until assayed. Most of the biochemical markers were
measured using an ILAB 600 analyser (Instru men -
tation Laboratory, Milan, Italy). Total cholesterol (TC)
and triglycerides (TG) were assayed using routine
enzymatic methods. HDL-C was quantified using the
same enzymatic method after precipitation of the
plasma with phosphotungstic acid in the presence of
magnesium ions (15). The concentration of LDL-C
was calculated using the Friedewald formula (16).
hsCRP was measured using a latex-enhanced
immuno turbidimetric method (Tina-quant CRP
Roche, Indianapolis, USA). We excluded individuals
with hsCRP ≥ 10 mg/L, a level considered to be
indicative of a clinically-relevant inflammatory condi-
tion. PTX3 was measured by ELISA (Human
Pentraxin3 DuoSet ELISA R&D Systems, Minneapolis,
USA). 
Statistical analysis
Data are shown as mean ± standard deviation
for normally-distributed continuous variables and re l -
ative to absolute frequencies for categorical variables.
As the distributions of TG, hsCRP and PTX3 were
skewed, data were log-transformed for analysis and
presented as geometrical means and 95% confidence
intervals (CIs). Continuous variables were compared
using Student’s t test and ANOVA with the Tukey’s
post hoc test for subgroup differences. Categorical
variables were analysed using Chi-square tests for
contingency tables. Univariate associations were eval-
uated by Pearson’s linear correlation analysis.
Independent association of higher hsCRP and PTX3
with significant stenosis was tested using binary logis-
tic regression analysis. Adjustments were made to
correct the influence of hsCRP, traditional non-lipid
and lipid risk factors (age, BMI, W/H ratio, TC, LDL-
C, HDL-C and TG) on PTX3. Odds ratio (OR) and
95% CI were calculated. Predictive and discriminative
abilities of these models were assessed by the
Hosmer–Lemeshow goodness of fit test and by the
area under the receiver operating characteristic
(ROC) curve (AUC), respectively. The former com-
pares the observed frequencies of patients with the
event of interest with the expected frequencies based
on the values of the estimated probabilities obtained
by the logistic regression models. In this test, a high
p-value (non-significant) indicates that the model is
performing well and has a good fit. The AUC ranges
from 0 to 1 and provides a measure of the model’s
ability to discriminate between those subjects who
experience the outcome of interest and those who do
not. An AUC equal to 0.5 means no classification
accuracy. Swets (17) suggested the following guide-
lines for interpretation of the area under ROC curves
(AUCs): 0.5–0.7 low accuracy; 0.7–0.9 accuracy
useful for some purposes; and >0.9, high accuracy.
To compare the AUCs from each of these models, the
method described by DeLong et al. was used (18). 
The net reclassification index (NRI) was also cal-
culated. NRI summarizes the net proportion of indi-
viduals with »correct« reclassification (e.g., those who
develop events were up-classified, and those who do
not develop events were down-classified) and »incor-
rect« reclassification (those who develop events who
were down-classified, and those who do not develop
events who were up-classified) (19). A two-tailed p
value of p≤0.05 was considered significant. 
Results
Demographic characteristics of the 93 patients
are presented in Table I. The prevalence of males was
higher in CAD(1–3) patients than in CAD(0) patients.
In addition, a higher W/H ratio and prevalence of
smokers were also apparent in CAD(1–3) patients.
CAD(1-3) patients had higher concentrations of
hsCRP and PTX3 than CAD(0) patients. 
Demographic characteristics and plasma levels
of lipids and inflammatory markers in patients with
different extent of coronary stenosis are presented in
Table II. Levels of PTX3 and hsCRP in CAD(1–3)
patients were significantly different between sub-
groups with different extents of coronary stenosis
(p<0.001 and p=0.001, respectively). Concentration
of PTX3 showed an increasing trend with the increas-
ing number of vessels affected. We found significant-
ly higher values of PTX3 in CAD(2) (p=0.008) and
CAD(3) (p=0.014) subgroups, compared with the
CAD(0) group. CAD(2) and CAD(3) subgroup levels
of hsCRP were also significantly greater than in the
CAD(0) subgroup (p<0.001 and p<0.025, respec-
tively). In addition, hsCRP levels were significantly
higher in CAD(2) than in CAD(1) subgroup
(p=0.007).
As hsCRP concentrations lower than 3 mg/L
define subjects without high risk of CAD and values
higher than 3 mg/L define those with high risk for
CAD, we divided the patients into two groups accord-
ing to their hsCRP concentration and each group was
additionally separated into CAD(1–3) and CAD(0)
patients. PTX3 levels significantly differed between
the groups (ANOVA, p=0.003). In the group without
high risk defined on the basis of hsCRP concentra-
tion, PTX3 means for CAD(0) and CAD(1–3) patients
did not differ significantly (p=0.999, post hoc Tukey
test). However, in the group of high risk patients,
those with significant stenosis had higher PTX3 val-
ues compared with those without significant stenosis
(p=0.01), Figure 1. There were no significant differ-
ences in hsCRP concentrations between patients with
and without significant stenosis in the group without
high risk (p=0.999) and in the high risk group
(p=0.999), Figure 2. 
hsCRP and PTX3 concentrations were not sig-
nificantly correlated, either in the group with low
hsCRP levels (r=0.242, p=0.138), or in the group
with high hsCRP levels (r=0.167, p=0.323). PTX3
inversely correlated only with HDL-C (r=–0.142,
p=0.047) when all subjects were considered together.
ORs from binary logistic regressions and the
corresponding 95% CI for PTX3 and hsCRP are
presented in Table III. Both PTX3 (OR=1.133;
p<0.001) and hsCRP (OR=1.057; p=0.006) were
associated with the presence of significant CAD. The
models were built adjusting for conventional lipid and
non-lipid risk factors: the first (PTX3 was adjusted for
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Table I Demographic characteristics and plasma levels of lipids and inflammatory markers in CAD(1–3) and CAD(0) patients.
Variable CAD(0) patients CAD(1– 3) patients P-value
N 43 50
Male/female, (N) 21/22 38/12 0.011
Age, y 60.43±12.44 61.32±10.79 0.671
BMI, kg/m2 26.32±3.27 27.11±3.94 0.207
HT, % 34.9 28.0 0.559
Smokers, % 40.9 76.0 0.010
W/H ratio 0.91±0.10 0.96±0.09 0.003
TC, mmol/L 4.89±1.13 5.05±1.87 0.542
TG, mmol/L* 1.41 (1.22–1.63) 1.57 (1.33–1.86) 0.174
HDL-C, mmol/L 1.24±0.32 1.08±0.32 0.006
LDL-C, mmol/L 2.94±0.93 3.20±1.44 0.215
hsCRP, mg/L* 2.71 (1.81–4.05) 5.83 (3.53–9.63) 0.001
PTX3 * 3.96 (3.13–5.01) 6.72 (4.58–9.85) <0.001
Continuous variables are presented as mean ±1 SD, and categorical variables are presented as absolute and relative frequencies.
* For TG, hs-CRP and PTX3 the geometrical mean and 95% confidence interval (CI) are presented (BMI – body mass index; HT
– hypertension; W/H – waist-to-hip ratio; TC – total cholesterol; TG – triglycerides; HDL-C – HDL-cholesterol; LDL-C – LDL-cho-
lesterol; hsCRP – high-sensitivity C-reactive protein; PTX3 – pentraxin-3).
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Table II Demographic characteristics and plasma levels of lipids and inflammatory markers in patients with different stage of coro-
nary stenosis.
Variable CAD(0) CAD(1) CAD(2) CAD(3) P-value
N 43 14 20 16
Age, y 60.43±12.44 61.00±14.01 60.44±10.76 62.75±8.86 0.909
BMI, kg/m2 26.32±3.27 25.44±3.13 27.82±5.28 27.69±2.25 0.109
W/H ratio 0.91±0.10 0.95±0.10 0.96±0.09 0.96±0.07 0.234
TC, mmol/L 4.89±0.72 4.60±0.72 5.02±2.06 5.48±2.36 0.711
TG, mmol/L* 1.41 (1.22–1.63) 1.25 (0.92–1.69) 1.59 (1.19–2.12) 1.88 (1.32–2.67) 0.289
HDL-C, mmol/L 1.24±0.32 1.21±0.27 1.05±0.40 1.01±0.33 0.162
LDL-C, mmol/L 2.94±0.93 2.80±0.58 3.20±1.52 3.56±1.90 0.545
hsCRP, mg/L* 2.71 (1.81–4.05) 2.34 (0.81–6.74) 9.55 (4.25–21.45)a,b *** 7.01 (2.96–16.66)a, ** <0.001
PTX3 * 3.96 (3.13–5.01) 4.71(1.86–11.90) 7.62 (3.73–15.56)a, ** 7.83 (4.04–15,16)a, * 0.001
1 Continuous variables were compared by ANOVA and categorical variables by Chi-square test.
2 TG, hsCRP and PTX3 concentrations were presented as geometrical mean and 95% confidence interval (CI) for mean.
***P<0.001; **P<0.01; *P<0.05 (Tukey’s post hoc test).
a Significantly different from CAD(0) by Tukey’s post hoc test.
b Significantly different from CAD(1) by Tukey’s post hoc test.
(BMI – body mass index; HT – hypertension; W/H – waist-to-hip ratio; TC – total cholesterol; TG – triglycerides; HDL-C – HDL-
cholesterol; LDL-C – LDL-cholesterol; hsCRP – high-sensitivity C-reactive protein; PTX3 – pentraxin-3)
Figure 1 Geometrical means of PTX3 in groups of patients at low and high risk for CAD, based on hsCRP level and with addi-
tional separation into patients with subclinical [CAD(0)] and significant stenosis [CAD(1-3)].
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hsCRP, and hsCRP was adjusted for PTX3); the sec-
ond, adjusting for demographic data (age, BMI and
W/H ratio); and the third, adjusting for lipid status
parameters (TC, TG, HDL-C and LDL-C) (Table III). 
When taking concentrations of PTX3 into
account, elevated hsCRP was linked with significant
stenosis (p=0.045). The association between elevat-
ed PTX3 and significant stenosis remained strong
after adjustment for the concentrations of hsCRP
(p=0.002). 
The adjustment for demographic and lipid fac-
tors changed the association of PTX3 and significant
stenosis only slightly (Table III). The association
between PTX3 and CAD stenosis remained strong,
regardless of the confounding variables.
The diagnostic ability of PTX3 and hsCRP for
the screening of significant stenosis was investigated
by ROC curve analysis (Table IV). hsCRP and PTX3
had low discriminative ability for detection of signifi-
cant stenosis using Swets’ criteria. A combination of
PTX3 with hs-CRP slightly increased the discrimina-
tive abilities of hsCRP and PTX3 alone. The potential
benefit of adding PTX3 or/and hsCRP to non-lipid
(model 2) and lipid (model 3) parameters was tested
for discriminating subjects with CAD(1–3) from sub-
jects with CAD(0). The addition of hsCRP or/and
PTX3 to model 2 slightly increased the AUC, without
statistical significance (from 0.03 to 0.05) and NRI
(7% for model 2 with hsCRP and PTX3). On the other
hand, the AUC for lipid parameters (model 3)
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Figure 2 Geometrical means of hsCRP in groups of patients at low and high risk for CAD, based on hsCRP level and with addi-
tional separation into patients with subclinical [CAD(0)] and significant stenosis [CAD(1–3)].
Table III Logistic regression analysis for the association of elevated hsCRP and PTX with significant stenosis.
hsCRP PTX
OR (95% CI) p OR (95% CI) p
Unadjusted1 1.057 (1.016–1.099) 0.006 1.133 (1.060–1.210) <0.001
Adjusted:
Model 1 1.042 (1.001–1.084) 0.045 1.113 (1.042–1.188) 0.002
Model 2 1.052 (1.007–1.099) 0.023 1.133 (1.051–1.221) 0.001
Model 3 1.056 (1.011–1.104) 0.015 1.145 (1.060–1.236) 0.001
1hsCRP and PTX3 were entered as continuous variables.
Model 1, PTX3 adjusted for hsCRP and hsCRP adjusted for PTX3; model 2 adjusted for age (years), BMI (kg/m2) and W/H ratio;
model 3, adjusted for TC (mmol/L), TG (mmol/L), HDL-C (mmol/L) and LDL-C (mmol/L).
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increased significantly after the inclusion of hsCRP
and PTX3 combinations in model 3 (AUC=0.69 vs.
AUC=0.77; p=0.024) as did the goodness of fit.
The AUCs for the combinations of hsCRP and PTX3
with lipid parameters (model 3) were higher than all
combinations of those parameters with non-lipid
parameters and had useful accuracy for detecting
CAD(1–3) patients (AUC=0.770, p<0.001). In addi-
tion, NRI increased by 3.2% , 4.3% and 7.0% after
inclusion of hsCRP, PTH3 and hsCRP and PTX3,
respectively to model 2. Increase in NRI was higher
after addition of these parameters to the model 3:
5.9% for addition of hsCRP, 9.1% for addition of
PTX3 and 13.5% for addition of hsCRP and PTX3.
Discussion
Atherosclerosis is a multifactorial disease whose
etiology involves inflammatory, immune and hemo-
static factors (18). The role of hsCRP in atherosclero-
sis and as a marker of inflammation has been inten-
sively studied in the past years (3, 5). PTX3 appeared
more recently as a biomarker, and although its role in
atherosclerosis has not yet been clarified, studies have
shown that PTX3 has tissue-protective and anti-
inflammatory properties (9, 21, 22). PTX3 is rapidly
induced at the tissue level and released in plasma at
sites of myocardial infarction, atherosclerosis, vascu-
lar damage, or inflammation (12). PTX3 is a selective
marker of vascular activation associated with athero-
sclerosis (6), and its concentration in plasma reflects
local inflammation at the site of atherosclerotic lesion
itself (8).
In this study, we found significantly lower PTX3
and hsCRP concentrations in CAD(0) compared to
CAD(1–3) patients. We also found statistically higher
concentrations of PTX3 and hsCRP in CAD(2) and
CAD(3) subgroups, when compared with the group
of patients without significant stenosis. These findings
regarding hsCRP confirmed the results of Memon et
al. from a 2006 study on a similar but larger group of
patients undergoing coronary angiography for sus-
pected CAD (23). Our results of the relationship
between hsCRP level and the progression of coronary
artery stenosis were to be expected and in agreement
with previous studies [Arthurs et al., 2008 (24),
Kadoglou et al., 2008 (25), Sadat et al., 2009 (26)].
The cause of increased serum PTX3 levels in patients
with significant stenosis is still unknown. PTX3 is pre-
dominantly released by inflamed tissue in response to
the proinflammatory cytokines tumor necrosis factor
a and interleukin-1b, microbial components, or bio-
chemical substances (such as HDL and oxidized
LDL). Therefore, the elevated serum PTX3 levels may
reflect local inflammation. PTX3 may also be
released from circulating neutrophils (27), but under
conditions of massive leukocyte activation, the release
of PTX3 acts locally as a negative feedback mediator,
dampening leukocyte recruitment. This pathway
underlies the regulatory role of PTX3 in inflammation
(21). 
We found a significant negative correlation of
PTX3 with HDL-C, similar to the results obtained in
the study of Zanetti et al. (6) on a group of patients
with metabolic syndrome and subclinical atherosclero-
sis. This negative correlation shows that the anti-
inflammatory role of PTX3 is doubtful, in regard to the
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Table IV The results of ROC analysis for discriminating significant from subclinical coronary stenosis.
AUC (95% CI) p HL chi2
hs-CRP 0.66 (0.52–0.79) 0.031 14.35*
PTX3 0.67 (0.54–0.81) 0.017 8.41*
hsCRP and PTX3 0.71 (0.57–0.85) 0.004 11.09*
Model 2 0.68 (0.54–0.81) 0.020 14.03*
Model 2 and hsCRP 0.71 (0.58–0.84) 0.006 6.85*
Model 2 and PTX3 0.71 (0.58–0.85) 0.005 33.54
Model 2, hsCRP and PTX3 0.74 (0.60–0.87) 0.002 7.25*
Model 3 0.69 (0.56–0.82) 0.013 8.54*
Model 3 and hsCRP 0.761 (0.63–0.89) 0.001 12.20*
Model 3 and PTX3 0.74 (0.61–0.88) 0.002 21.73
Model 3, hsCRP and PTX3 0.772 (0.64–0.90) <0.001 13.29*
Hosmer-Lemeshow (HL) tests based on 10 groups.
*Significant HL goodness of fit, p>0.05; 1significantly different from model 2; 2significantly different from model 3.
established protective effects of HDL-C against CAD.
Low HDL-c is a strong predictor for CVD, and whether
PTX3 in this inverse correlation with HDL-C increases
the impact of dyslipidemia on cardiovascular risk, or
increased PTX3 have an anti-inflammatory role,
needs to be examined in the future. Haybar et al. (30)
showed that in the presence of PTX3, HDL-C is no
longer protective against CAD. Miya moto et al. (9)
found positive correlation between PTX3 and HDL-C
in hemodialysis patients and explained their results
with HDL-C stimulating PTX3 mRNA expression and
protein release in endothelial cells, leading to an
assumption about the involvement of PTX3 in the
atheroprotective effects of HDL-C. The distinction in
results can be attributable to the different groups of
patients involved in studies, or the complex relation-
ships between PTX3, lipid parameters and stage of
atherosclerosis in different pathologies. Norata et al.
(12) and Inoue et al. (28) suggest that the increase of
pentraxins in atherosclerosis could not be regarded as
a harmful response but rather a further attempt to pro-
tect our body. Accumulated evidence from in vivo
studies indicates that, although the predominant role
of PTX3 is host-protective, the multi-functional prop-
erties of PTX3 make it somewhat host-destructive as
well. 
We found a difference in PTX3 levels between
CAD(0) and CAD(1–3) patients in the group without
high risk as well as in the group with high risk, defined
on the basis of hsCRP, though the levels of PTX3 were
very similar in CAD(1–3) patients in both groups
(Figure 1). Our results indicate that PTX3 is more
influenced by stenosis than CRP. hsCRP alone had
insufficient specificity for CAD because some patients
with CAD(1–3) had low hsCRP concentrations, and
vice versa, patients with high hsCRP had no stenosis.
The use of PTX3 in the group of patients identified to
be at high risk would lead to better reclassification of
patients into groups with and without significant
stenosis, if this marker is measured simultaneously
with hsCRP. In the group with high risk based on
hsCRP, CAD(0) patients still had low average PTX3
concentrations. It can be assumed that PTX3 could
be more successful for identifying CAD(0) individuals
who are classified in the high risk group based on
hsCRP level, and this opens up the possibility for fur-
ther research to determine cut-off values for PTX3 in
a larger group of patients. 
We found no correlation between PTX3 and
hsCRP in those groups. Studies of Ogawa et al. (29)
and Jylhava et al. (2) also showed no correlation
between PTX3 and hsCRP. 
We assessed whether measurement of PTX3
had any potential in predicting risk for development of
significant coronary stenosis. We found a more signif-
icant link between levels of circulating PTX3 and
coronary stenosis, than those observed for hsCRP,
based on the odds ratio. This difference between
PTX3 and CRP may be explained with the release of
PTX3 locally, at the site of stenosis, compared to liver-
restricted release of CRP, according to Hollan et al.
(27), and Jylhava et al. (2).
Our analysis indicated that the influence of
PTX3 on the appearance of severe stenosis was inde-
pendent on demographic factors, lipid status param-
eters and hsCRP. We had similar findings for hsCRP,
which was also independent of demographic factors,
lipid parameters and PTX3 as a predictor for coronary
stenosis.
Circulating PTX3 has been shown to function as
a fast responding biomarker in cardiovascular
pathologies (8), and this reflects the degree of local
inflammation in coronary atherosclerosis. Haybar et
al. (30) showed that PTX3 in the coronary sinus and
femoral artery predict the probability of CAD among
intermediate-risk populations with stable angina inde-
pendently of the established CAD risk factors. The
MONICA-KORA case-cohort study (2006) showed
that the increased concentration of hsCRP remained
strong and was an independent predictor of CVD risk
in men even after adjustment for traditional cardio-
vascular risk factors, lipid parameters and for another
potent inflammatory marker, interleukin-6 (31). Our
study may contribute to identifying the best combina-
tion of inflammatory markers for risk assessment of
future cardiovascular events. 
ROC analysis showed that hsCRP and PTX3
alone have moderate ability to separate CAD(1–3)
from CAD(0) subjects. Thus, our findings were simi-
lar to those obtained for these two markers in the
studies of Tong et al. (32) and Tamura et al. (33).
ROC curve analysis showed that the AUC for deter-
mining these two parameters together was greater
than 0.7. 
Therefore, we performed tests to discriminate
and calibrate different prediction models. Discri mi -
native analysis of a model with lipid parameters and
hsCRP and PTX3 showed that the AUC increased sig-
nificantly. The predictive performance also improved.
Considering the other new statistical metrics, pro-
posed recently to quantify the degree of correct
reclassification, the inclusion of hsCRP and PTX3 in a
model with lipid parameters was associated with an
NRI impro vement of 13.5%, suggesting moderately
effective reclassification. Thus, the combination of
hsCRP and PTX3 provided a better tool for risk strat-
ification than either factor alone and supports the the-
ory that the scores for risk assessment should be sup-
plemented with inflammatory parameters. 
Until now, evidence on which emerging bio-
marker is more suitable for the diagnosis or prognosis
of CAD has been inconsistent. Several authors have
concluded that high hsCRP is associated with
increased prevalence of myocardial infarction: de
Ferranti et al. in their study suggested that hsCRP
augments the predictive capacity of the Framingham
Risk Score (FRS) (20), Tamon et al. (34) presented
the relationship of hsCRP with FRS (34), Koenig et al.
J Med Biochem 2015; 34 (4) 447
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(35) showed that CRP enhances global coronary risk
as assessed by FRS, especially in intermediate risk
groups. In contrast, Cristell et al. established limita-
tions of hsCRP as an individual prognostic marker and
as an indicator of a generalized inflammatory patho-
genic component of myocardial infarction with ST-
elevation. The main weakness of this biomarker is its
systemic inflammatory role. However, PTX3, being a
marker of local inflammation, is independent of sys-
temic inflammatory status and this might be a poten-
tial advantage of PTX3 in coronary disease prediction
compared with hsCRP. 
Our study showed that increased circulating levels
of PTX3 and hsCRP represent inflammatory markers of
advanced atherosclerosis in patients with CAD, and
both markers might be quantitative indicators of disease
extent. It would be best if we could have compared the
values obtained in the patients with the corresponding
values found in a group of stenosis-free subjects.
However, as coronary angiography is an aggressive
method, it is never performed without a good reason,
and it is impossible to recruit such a group.
PTX3 is a promising independent diagnostic
marker for identifying patients with CAD, and a use-
ful indicator of disease progression. In all analyses
PTX3 showed better performance than CRP. A com-
bination of PTX3, hsCRP and lipid status parameters
provides risk stratification of the development of coro-
nary stenosis and better classification than their indi-
vidual application. Finding the best combination of
biomarkers for assessing coronary stenosis develop-
ment is our future aim.
Limitations
Use of PTX3 as a marker to improve reclassifi-
cation of patients with CAD is limited until it becomes
widely available on immunochemistry platforms.
How ever, the commercially available PTX3 assay
used in our study is simple to perform and the results
are available within a few hours. The cost per sample
of PTX3 measurement is less compared to the pro-
hibitive healthcare costs of the management of CAD
complications. Additionally, hsCRP and PTX3 after
inclusion in different models gave only useful accura-
cy for discrimination of patients with and without sig-
nificant stenosis and cost-effectiveness studies are
needed to evaluate their utility value. It can be
assumed that PTX3 could be a successful marker for
improving reclassification of patients with CAD, but
the limitation of this study is the small group of
patients included, and this opens up the possibility for
further research on a larger group of patients. 
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